

The logo for UK NEQAS, featuring the text 'UK NEQAS' in a bold, blue, sans-serif font. A small blue checkmark is positioned to the right of the 'Q'.

Leucocyte Immunophenotyping

[www.ukneqasli.co.uk](http://www.ukneqasli.co.uk)

A detailed, colorful microscopic image of a cell, likely a lymphocyte, showing its internal structure. The cell is stained with various dyes, highlighting its nucleus, cytoplasm, and surface receptors. The image is set against a soft, warm background.

# New Information for 2020/2021

EQA Programmes for  
Molecular Haemato-Oncology

The logo for EQA International, featuring the letters 'EQA' in a stylized, bold font with a blue and orange color scheme, followed by the word 'International' in a blue, sans-serif font. Below the logo is the tagline 'Working in partnership with UK NEQAS LI' in a smaller, blue font.

**EQA**International  
Working in partnership with UK NEQAS LI

[www.eqainternational.com](http://www.eqainternational.com)

## CHANGES TO CURRENT PROGRAMMES

### JAK2 p.Val617Phe (V617F) Mutation Status (Accredited)

UK NEQAS LI will be piloting a new quantitative performance monitoring system (based on mutation load) to supplement the pre-existing qualitative (mutation present/mutation absent) performance monitoring system.

---

### FLT3 Mutation Status (Accredited)

Data entry returns will require submission of allelic ratio information (mutant/wildtype) based on European Leukaemia Network guidelines (Döhner et al., 2017).

In addition, at least one educational sample will be issued in a trial year for *FLT3* tyrosine kinase domain (TKD) variant testing.

---

## NEW PROGRAMME

### MRD-AML by Molecular Genetics (Pre-Pilot - Not Accredited)

Measurable residual disease (MRD) testing is an independent prognostic marker, increasingly important for risk stratification and patient management in acute myeloid leukaemia.

This new programme is designed to assess a laboratories ability to detect and quantify by molecular methods the t(8;21) *RUNX1-RUNX1T1*, inv(16) *CBFB-MYH11*, and t(15;17) *PML-RARA* rearrangements, as well as *NPM1* variants, in line with recommendations from the European LeukaemiaNet AML MRD working group (Schuurhuis et al, 2018).

**Please contact [admin@ukneqasli.co.uk](mailto:admin@ukneqasli.co.uk) if you wish to be part of this study. This scheme will be free of charge for 2020-2021. Limited places are available.**

Should you wish to participate in any of the above programmes please contact:

UK NEQAS LI  
Pegasus House  
4<sup>th</sup> Floor Suite  
463a Glossop Road  
Sheffield, S10 2QD  
United Kingdom

Tel: +44 (0)114 2673600 | Fax: +44 (0)114 2673601  
email: [admin@ukneqasli.co.uk](mailto:admin@ukneqasli.co.uk) | [www.ukneqasli.co.uk](http://www.ukneqasli.co.uk)

Please note that if your participation with UK NEQAS LI is via a non-UK distributor (and is outside of the UK) you should contact them directly for details of how to register.